Cover Image
市場調查報告書

鴉片 (類鴉片物質) 中毒:開發中產品分析

Opium (Opioid) Addiction - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192749
出版日期 內容資訊 英文 99 Pages
訂單完成後即時交付
價格
Back to Top
鴉片 (類鴉片物質) 中毒:開發中產品分析 Opium (Opioid) Addiction - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 99 Pages
簡介

類鴉片物質中毒,在某時期定期使用類鴉片物質之後發病。鴉片 (鎮靜劑)的長期使用,會引起腦內的神經病變。由於減輕疼痛的神經細胞的變性,帶來身體對外部供給來源的鴉片 (鎮靜劑) 的依賴。徵兆和症狀,有強烈不安感,高昂感,精神病,抑鬱感,高血壓,食慾衰退,身體的興奮,睡眠障礙,骨頭疼痛等。原因有年齡,藥物濫用的既往經歷,藥物濫用的家族病史,香煙的依賴,精神的壓力等。

本報告提供鴉片 (類鴉片物質) 中毒的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

鴉片 (類鴉片物質) 中毒概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

鴉片 (類鴉片物質) 中毒:企業開發中的治療藥

鴉片 (類鴉片物質) 中毒:大學/機關研究中的治療藥

鴉片 (類鴉片物質) 中毒:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

鴉片 (類鴉片物質) 中毒:企業開發中的產品

鴉片 (類鴉片物質) 中毒:大學/機關研究中的產品

鴉片 (類鴉片物質) 中毒的治療藥的開發企業

  • Alkermes Plc
  • Aoxing Pharmaceutical Company, Inc
  • BioDelivery Sciences International, Inc.
  • Camurus AB
  • Foresee Pharmaceuticals, LLC
  • Heron Therapeutics, Inc.
  • Indivior Plc
  • INSYS Therapeutics, Inc.
  • Omeros Corporation
  • Pfizer Inc.
  • Relmada Therapeutics, Inc.
  • Titan Pharmaceuticals, Inc.
  • Zynerba Pharmaceuticals, Inc.

鴉片 (類鴉片物質) 中毒:治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

鴉片 (類鴉片物質) 中毒:最近的開發平台趨勢

鴉片 (類鴉片物質) 中毒:暫停中的計劃

鴉片 (類鴉片物質) 中毒:開發中止的產品

鴉片 (類鴉片物質) 中毒:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8488IDB

Summary

Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H2 2016', provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
  • The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Opium (Opioid) Addiction Overview
  • Therapeutics Development
    • Pipeline Products for Opium (Opioid) Addiction - Overview
    • Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis
  • Opium (Opioid) Addiction - Therapeutics under Development by Companies
  • Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes
  • Opium (Opioid) Addiction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Opium (Opioid) Addiction - Products under Development by Companies
  • Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes
  • Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
    • Alkermes Plc
    • Aoxing Pharmaceutical Company, Inc
    • BioDelivery Sciences International, Inc.
    • Camurus AB
    • Foresee Pharmaceuticals, LLC
    • Heron Therapeutics, Inc.
    • Indivior Plc
    • INSYS Therapeutics, Inc.
    • Omeros Corporation
    • Pfizer Inc.
    • Relmada Therapeutics, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Titan Pharmaceuticals, Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Opium (Opioid) Addiction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride depot - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride long acting - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORP-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-5006739 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • samidorphan l-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TA-CD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TEV-90109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Opium Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Opium (Opioid) Addiction - Dormant Projects
  • Opium (Opioid) Addiction - Discontinued Products
  • Opium (Opioid) Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Aug 16, 2016: Indivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder
      • Aug 02, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Juan on August 5, 6 and 7 for Qualified Healthcare Providers
      • Jul 26, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Burlington on July 29 and 30 for Qualified Healthcare Providers
      • Jul 19, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings on July 22, 23 and 24 for Qualified Healthcare Providers in US
      • Jul 19, 2016: Buprenorphine implants may be effective relapse prevention tool for adults with opioid dependence
      • Jul 12, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Tampa on July 15, 16 and 17 for Qualified Healthcare Providers
      • Jun 29, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Antonio on July 8 and 9 for Qualified Healthcare Providers
      • Jun 21, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in St. Louis on June 24 and 25 for Qualified Healthcare Providers
      • Jun 20, 2016: Titan Pharmaceuticals Announces First Patients Treated With Probuphine For Opioid Dependence
      • Jun 16, 2016: Probuphine (buprenorphine) Implant Phase 3 Data Presented at CPDD Annual Scientific Meeting
      • Jun 15, 2016: Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine for Opioid Dependence
      • Jun 14, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Francisco on June 17, 18 and 19 for Qualified Healthcare Providers
      • Jun 13, 2016: Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine
      • Jun 09, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Louisville on June 10, 11 and 12 for Qualified Healthcare Providers
      • Jun 07, 2016: MonoSol Rx Wins Patent Infringement Suit Against Par Pharmaceutical and Watson Pharmaceuticals Related to Suboxone Sublingual Film
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Opium (Opioid) Addiction, H2 2016
  • Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2016
  • Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2016
  • Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2016
  • Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2016
  • Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
  • Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H2 2016
  • Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2016
  • Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2016
  • Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H2 2016
  • Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2016
  • Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Opium (Opioid) Addiction - Dormant Projects, H2 2016
  • Opium (Opioid) Addiction - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Opium (Opioid) Addiction, H2 2016
  • Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top